Rhythm Pharma Q4 2022 product revenue $8.8M, net loss $42.5M; BBS launch >200 scripts

RHYTHM PHARMACEUTICALS, INC.

2022-FY EPS reported -$3.47 revenue$23,638,000

Product revenue $8.8M Q4 2022, $16.9M FY; net loss $42.5M ($0.75/sh) Q4, $181.1M ($3.47/sh) FY.
IMCIVREE for BBS: >200 new scripts from >125 physicians, >100 reimbursement approvals since FDA approval June 2022.
Acquired Xinvento B.V. for congenital hyperinsulinism; founder Claudine van der Sande joins as VP, Head of CHI Program.
Initiated pivotal Phase 3 trial for setmelanotide in acquired hypothalamic obesity; patient screening underway.
FY 2023 non-GAAP operating expense guidance $200M-$220M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

RHYTHM PHARMACEUTICALS, INC. reported the fourth quarter ended December 31, 2022 results: revenue $8.8 million.

Period: the fourth quarter ended December 31, 2022
Revenue: $8.8 million
Result: reported results

Exact text from the filing

• Revenue: Product revenue, net relating to global sales of IMCIVREE was $8.8 million for the fourth quarter of 2022

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

RHYTHM PHARMACEUTICALS, INC. reported the year ended December 31, 2022 results: revenue $16.9 million.

Period: the year ended December 31, 2022
Revenue: $16.9 million
Result: reported results

Exact text from the filing

as $8.8 million for the fourth quarter of 2022 and $16.9 million for the year ended Decem

View on SEC.gov

Browse all earnings releases →

RHYTHM PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001104659-23-026995

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.